Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
Introduction: IDegLira (brand name Xultophy) is a novel fixed ratio combination of insulin degludec and liraglutide for type 2 diabetes (T2D) patients. This study aimed to investigate the lifetime cost-effective value of IDegLira compared with its single component (Degludec or Liraglutide) and to ex...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Livro |
| Publicado em: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
| Assuntos: | |
| Acesso em linha: | Connect to this object online. |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Área/Cota: |
A1234.567 |
|---|---|
| Cód. Barras: 1 | Disponível |